Limits...
Ellagic acid alleviates adjuvant induced arthritis by modulation of pro- and anti-inflammatory cytokines

View Article: PubMed Central - PubMed

ABSTRACT

Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown aetiology, but it is now clear that pro-inflammatory cytokines play a central role in its pathogenesis. Ellagic acid (EA) has a variety of biological activities including anti-oxidant, anti-inflammatory, and anti-cancer properties. The aim of the present study was to evaluate the potential effect of ellagic acid on the prevention and/or treatment of adjuvant induced arthritis (AIA) model in mice. Ellagic acid treatment was started one week before AIA induction and continued for three weeks after induction of AIA. Ellagic acid treatment significantly (p < 0.01) inhibited foot paw oedematous swelling and attenuated AIA-associated pathology. Ellagic acid significantly (p < 0.01) reduced serum levels of pro-inflammatory cytokines: interleukin 1β (IL-1β), tumor necrosis factor α (TNF-α), and interleukin 17 (IL-17). However, serum levels of IL-10 and interferon γ (IFN-γ) significantly increased (p < 0.01 and p < 0.05, respectively), while serum level of transforming growth factor β (TGF-β) did not significantly alter with EA treatment. In conclusion, these results suggest that EA attenuated AIA-associated pathology in the mouse model by downregulation of pro-inflammatory cytokines and upregulation of anti-inflammatory cytokines.

No MeSH data available.


Related in: MedlinePlus

The effect of ellagic acid treatment on the histopathological arthritis score of arthritic control (AC) and arthritic treated (AT) mice. The histopathological score of synovitis, pannus formation, bone resorption and cartilage destruction were examined per grades out of total score 12. Data reported as mean ± SD of 10 mice per each group. ** p < 0.01
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5382880&req=5

f0003: The effect of ellagic acid treatment on the histopathological arthritis score of arthritic control (AC) and arthritic treated (AT) mice. The histopathological score of synovitis, pannus formation, bone resorption and cartilage destruction were examined per grades out of total score 12. Data reported as mean ± SD of 10 mice per each group. ** p < 0.01

Mentions: Histologic analysis of synovitis, pannus formation, bone erosion, and cartilage destruction were scored on a 0-3 scale in H&E-stained sections by a blinded observer. The present data revealed a high significant (p < 0.01) reduction in the total histopathological score of AT mice compared to AC ones (Fig. 3). In detail, EA treatment significantly (p < 0.01) attenuated the synovitis, reduced pannus formation, and decreased bone resorption in treated mice, compared to control mice. However, cartilage destruction in AT mice did not change significantly (p > 0.05) as compared to AC mice (Fig. 3).


Ellagic acid alleviates adjuvant induced arthritis by modulation of pro- and anti-inflammatory cytokines
The effect of ellagic acid treatment on the histopathological arthritis score of arthritic control (AC) and arthritic treated (AT) mice. The histopathological score of synovitis, pannus formation, bone resorption and cartilage destruction were examined per grades out of total score 12. Data reported as mean ± SD of 10 mice per each group. ** p < 0.01
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5382880&req=5

f0003: The effect of ellagic acid treatment on the histopathological arthritis score of arthritic control (AC) and arthritic treated (AT) mice. The histopathological score of synovitis, pannus formation, bone resorption and cartilage destruction were examined per grades out of total score 12. Data reported as mean ± SD of 10 mice per each group. ** p < 0.01
Mentions: Histologic analysis of synovitis, pannus formation, bone erosion, and cartilage destruction were scored on a 0-3 scale in H&E-stained sections by a blinded observer. The present data revealed a high significant (p < 0.01) reduction in the total histopathological score of AT mice compared to AC ones (Fig. 3). In detail, EA treatment significantly (p < 0.01) attenuated the synovitis, reduced pannus formation, and decreased bone resorption in treated mice, compared to control mice. However, cartilage destruction in AT mice did not change significantly (p > 0.05) as compared to AC mice (Fig. 3).

View Article: PubMed Central - PubMed

ABSTRACT

Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown aetiology, but it is now clear that pro-inflammatory cytokines play a central role in its pathogenesis. Ellagic acid (EA) has a variety of biological activities including anti-oxidant, anti-inflammatory, and anti-cancer properties. The aim of the present study was to evaluate the potential effect of ellagic acid on the prevention and/or treatment of adjuvant induced arthritis (AIA) model in mice. Ellagic acid treatment was started one week before AIA induction and continued for three weeks after induction of AIA. Ellagic acid treatment significantly (p &lt; 0.01) inhibited foot paw oedematous swelling and attenuated AIA-associated pathology. Ellagic acid significantly (p &lt; 0.01) reduced serum levels of pro-inflammatory cytokines: interleukin 1&beta; (IL-1&beta;), tumor necrosis factor &alpha; (TNF-&alpha;), and interleukin 17 (IL-17). However, serum levels of IL-10 and interferon &gamma; (IFN-&gamma;) significantly increased (p &lt; 0.01 and p &lt; 0.05, respectively), while serum level of transforming growth factor &beta; (TGF-&beta;) did not significantly alter with EA treatment. In conclusion, these results suggest that EA attenuated AIA-associated pathology in the mouse model by downregulation of pro-inflammatory cytokines and upregulation of anti-inflammatory cytokines.

No MeSH data available.


Related in: MedlinePlus